Modalities
Every modality has a different manufacturing logic.
CDMO Network Europe helps sponsors route biological programs by modality, stage, host system, analytical burden, quality level, final format, and regional execution fit.
AAV is not mRNA. Exosomes are not recombinant proteins. Animal health is not classic human GMP. The network model exists because modern biology has fragmented into hundreds of serious product types, each requiring a different technical route.
Platform-specific.
Each modality has its own upstream, downstream, analytical, and quality logic.
Stage-specific.
Discovery, preclinical, clinical, commercial, and transfer programs need different partners.
Format-specific.
DS, DP, sterile fill, lyophilized, frozen, live, particle, and reagent formats change routing.
Region-specific.
Europe’s CDMO strengths vary by modality, capability, maturity, and manufacturing model.
Major Modality Families
Structured coverage across biological product classes.
The goal is not to say “we support biologics.” The goal is to map the real scientific category to the correct CDMO capability and execution path.
Antibodies & Engineered Binders
Classic and next-generation antibody programs requiring expression, purification, characterization, formulation, and GMP supply.
Recombinant Proteins & Enzymes
Therapeutic, diagnostic, food, industrial, and research proteins across microbial, yeast, mammalian, and insect systems.
Gene Therapy & Viral Vectors
Vector platforms requiring plasmid supply, producer systems, viral production, purification, potency, safety, and sterile fill.
RNA, DNA & LNP Platforms
Nucleic acid programs involving synthesis, plasmid templates, encapsulation, particle analytics, potency, and final sterile formats.
Cell Therapy & Regenerative Medicine
Cell-based programs requiring donor material, expansion, engineering, analytics, cryopreservation, release, and clinical logistics.
Exosomes & Extracellular Vesicles
EV and exosome programs needing cell culture, isolation, purification, particle analytics, biomarker panels, cargo analysis, and potency strategy.
Vaccines & Immunological Platforms
Vaccine modalities across recombinant antigens, viral platforms, VLPs, nucleic acids, adjuvants, fill-finish, and clinical supply.
Microbial & Live Biological Products
Programs involving bacterial, yeast, fungal, anaerobic, probiotic, synbiotic, or microbiome-based manufacturing and formulation.
Nanomedicine & Delivery Systems
Particle and delivery modalities requiring formulation control, size distribution, encapsulation, stability, release, and sterile presentation.
Modality Atlas
From mainstream biologics to the long tail of modern biotechnology.
The network model is built for breadth. A sponsor may need a standard mammalian biologics CDMO, a specialized viral-vector partner, an exosome analytics group, a microbial fermentation route, or a multi-partner execution chain.
Antibodies, binders & protein modalities
Gene therapy, vectors & viral systems
Nucleic acids, gene editing & delivery
Cell therapy & regenerative modalities
Microbial, yeast, fungal & live modalities
Exosomes, particles & emerging delivery
Animal health, food & industrial modalities
Rare, hybrid & edge-case modalities
Modality determines the route.
CDMO selection changes when the program changes from antibody to AAV, from LNP to exosome, from microbial enzyme to live biotherapeutic, or from human therapeutic to veterinary product. The network maps those differences before the wrong conversation starts.
Same word, different manufacturing reality.
“Biologic” is too broad. Each modality must be routed through its own technical logic.
Usually route through mammalian expression, purification, comparability, formulation, and GMP clinical or commercial biologics supply.
Require vector production, plasmid support, capsid analytics, potency, empty/full analysis, safety testing, and specialized fill-finish.
Need cell source logic, EV isolation, marker characterization, particle sizing, cargo analysis, potency strategy, and emerging CMC discipline.
Route by host, strain, fermentation mode, downstream recovery, impurity burden, drying or formulation, cost target, and quality framework.